Table 2 Clinical features of Parkinson’s disease subjects and healthy control subjects.
From: Deep nasal sinus cavity microbiota dysbiosis in Parkinson’s disease
PD | rHC | p-value | SpPD | SpHC | p-value | |
|---|---|---|---|---|---|---|
Total subjects | 30 | 17 | – | 11 | 11 | – |
Age | 60.12 (6.86) | 55.18 (11.09) | 0.64 | 58.4 (5.09) | 59.4 (5.2) | 0.65 |
Sex (% male) | 83% | 71% | 0.46 | 64% | 45% | 0.67 |
Age of onset | 54.69 (8.15) | – | – | 53.2 (7.88) | – | – |
Disease duration | 5.53 (4.81) | – | – | 14.1 (19.78) | – | – |
Total MDS-UPDRS | 30.1 (14.1) | – | – | 26.67 (9.32) | – | – |
MDS-UPDRS I | 5.5 (3.2) | – | – | 5.58 (3.26) | – | – |
MDS-UPDRS II | 5.4 (4.9) | – | – | 5 (2.86) | – | – |
MDS-UPDRS III | 17.8 (8.3) | – | – | 14.25 (4.47) | – | – |
MDS-UPDRS IV | 1.3 (2.5) | – | – | 1.83 (2.79) | – | – |
H&Y Stages | 1.9 (0.3) | – | – | 1.82 (0.40) | – | – |
LEDD | 400.8 (369.6) | – | – | 308.18 (245.72) | – | – |
UPSIT | 24.7 (6.7) | – | – | 26.2 (8.36) | 37 (2.7) | 0.02 |
